SCHEMBL6490737

SCHEMBL6490737

Cc1cn(C(=O)c2c(Cl)cccc2Cl)c2ccc(NC(=O)C3CCC3)cc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.46
JAK2 O60674 2/20 0.46
TYK2 P29597 2/20 0.46
JAK1 P23458 1/20 0.46
UBE2M P61081 1/20 0.44
DCUN1D1 Q96GG9 1/20 0.44
ALDH1A1 P00352 3/20 0.44
KDM4E B2RXH2 1/20 0.44
GAA P10253 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
ELANE P08246 2/20 0.44
MALT1 Q9UDY8 1/20 0.43
USP2 O75604 1/20 0.43
ALPL P05186 1/20 0.43
ALPI P09923 1/20 0.43
ALPG P10696 1/20 0.43
KMT2A Q03164 1/20 0.43
GBA1 P04062 1/20 0.42
GLA P06280 1/20 0.42
RAB9A P51151 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6481370 0.98 NPSR1 (0.49) NPSR1JAK2TYK2JAK1UBE2M
SCHEMBL6480497 0.96 UBE2M (0.46) NPSR1JAK2TYK2JAK1UBE2M
SCHEMBL6480297 0.81 NPSR1 (0.46) NPSR1JAK2TYK2JAK1UBE2M
SCHEMBL6491491 0.81 F2R (0.51) ALDH1A1KDM4EGAASMN1; SMN2ELANE
SCHEMBL6490317 0.79 NPSR1 (0.49) NPSR1JAK2TYK2JAK1ALDH1A1
SCHEMBL6490018 0.78 ALDH1A1 (0.47) ALDH1A1KDM4ESMN1; SMN2KMT2ARAB9A
SCHEMBL6185346 0.78 NPSR1 (0.48) NPSR1JAK2TYK2ALDH1A1KDM4E
SCHEMBL6480667 0.78 CHRNA7 (0.36) NPSR1TYK2ALDH1A1GAASMN1; SMN2
SCHEMBL6492262 0.78 NPSR1 (0.47) NPSR1JAK2TYK2JAK1UBE2M
SCHEMBL6491032 0.77 MEN1 (0.45) NPSR1JAK2TYK2JAK1UBE2M

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050215614-A1 Substituted indoles and their use as hcv inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215614-A1 Substituted indoles and their use as hcv inhibitors IDO1, IDO2, HAVCR2 NPSR1 556/4885JAK2 160/4885TYK2 2201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.